Longacting cabotegravir and rilpivirine dosed every 2 months in adults with HIV1 infection ATLAS2M 48week results a randomised multicentre openlabel phase 3b noninferiority study

Hans JaegerEdgar T OvertonGary RichmondGiuliano RizzardiniJaime Federico Andrade-VillanuevaE et al2023-05-042023-05-04WOS2352-3018https://hdl.handle.net/10539/35313Longacting cabotegravir and rilpivirine dosed every 2 months in adults with HIV1 infection ATLAS2M 48week results a randomised multicentre openlabel phase 3b noninferiority study